Monitoring functional serum antitumor necrosis factor antibody level in Crohns disease patients who maintained and those who lost response to anti-TNF

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1898-1904

  Yamada, Akihiro ^a   Sono, Koji ^a   Hosoe, Nobuo ^a   Takada, Nobuo ^a   Suzuki, Yasuo ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

antibodies to infliximab; Crohns disease; fluid phase enzyme immunoassay; infliximab maintenance therapy

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; FREUND ADJUVANT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; FLUID PHASE ENZYME IMMUNOASSAY; HUMAN; MAINTENANCE THERAPY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; COHORT STUDIES; CROHN DISEASE; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MONITORING, IMMUNOLOGIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78249238525     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21259     Document Type: Article

References (29)

1. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohns disease. Gastroenterology. 1999; 117: 761-769.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. ACCENT I Study Group. Lancet. 2002; 359: 1541-1549.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med. 1999; 340: 1398-1405.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004; 350: 876-885.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
6. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811.
7. Schreiber S, Nikolaus S, Hampe J,. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohns disease. Lancet. 1999; 353: 459-461.
8. Papadakis KA, Targan SR,. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51: 289-298.
9. Sandborn WJ,. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep. 2003; 5: 501-505.
10. Rudolph S, Weinberg DI, McCabe RP,. Long-term durability of Crohns disease treatment with infliximab. Dig Dis Sci. 2008; 53: 1033-1041.
11. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohns disease. Am J Gastroenterol. 2008; 103: 944-948.
12. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med. 2003; 348: 601-608.
13. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease. Clin Gastroenterol Hepatol. 2004; 2: 542-553.
14. Hennig C, Rink L, Fagin U, et al. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods. 2000; 235: 71-80.
15. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohns disease: a randomized controlled trial. Gastroenterology. 2003; 124: 917-924.
16. Cassinotti A, Travis S,. Incidence and clinical significance of immunogenicity to infliximab in Crohns disease: a critical systematic review. Inflamm Bowel Dis. 2009; 15: 1264-1275.
17. Bendtzen K,. Anti-IFN BAb and NAb antibodies: a minireview. Neurology. 2003; 61 (suppl 5): S6-10.
18. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohns disease. Inflamm Bowel Dis. 2007; 13: 1093-1099.
19. Gisbert JP, Panés J,. Loss of response and requirement of infliximab dose intensification in Crohns disease: a review. Am J Gastroenterol. 2009; 104: 760-767.
20. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohns disease. Clin Immunol. 2006; 118: 11-19.
21. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohns disease previously treated with infliximab. Ann Intern Med. 2007; 146: 829-838.
22. Aybay C, Ozel S, Aybay C,. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int. 2006; 26: 473-480.
23. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohns disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000; 6: 8-15.
24. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002; 46: 3151-3158.
25. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease. Gastroenterology. 2004; 126: 402-413.
26. REMICADE (infliximab) Prescribing Information. Malvern, PA: Centocor, December 2006.
27. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007; 46: 1828-1834.
28. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 253-256.
29. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to anti-TNF alpha therapy in psoriasis a retrospective, observational study. Br J Dermatol. 2009 [Epub ahead of print].